The short version of trans-3-hexenoyl fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-08-20 and is reviewed periodically as new material appears.
Several compounds share the GHRH framework, including sermorelin, the shorter 1-29 fragment, and other analogs built on the full 1-44 chain. Naming follows a common convention: a stem that identifies the peptide plus a suffix marking analog status. Reports may describe tesamorelin by its sequence fragment, as a GHRH(1-44) analog, or by its amino-terminal modification. Indexing the compound therefore requires searching all of these forms, since some older literature predates the current international nonproprietary name.
Tesamorelin is a synthetic peptide built from 44 amino acids and classified with the growth hormone–releasing hormone family. Its sequence corresponds to the human GHRH(1-44) backbone, carrying one structural change at the amino terminus. That change is a trans-3-hexenoyl group placed where the natural peptide would have an unmodified end. The modification is the feature that separates the compound from the endogenous hormone in name, in stability, and in how it is handled in the laboratory.
The hexenoyl cap slows the enzyme step that trims the amino terminus of native GHRH, the same step that shortens its active lifetime in circulation. As a result, the modified peptide persists longer in plasma than the unmodified hormone in side-by-side comparison. Receptor activity stays broadly comparable, because the added group sits away from the residues that contact the binding site. This combination, preserved receptor activity with reduced degradation, explains why the analog was developed instead of the native sequence.
Measuring the effect of a growth hormone-releasing hormone analogue requires markers that reflect pituitary output rather than the peptide itself. The two most frequently used are growth hormone and insulin-like growth factor 1. Growth hormone fluctuates sharply across the day and responds to sleep, stress, and meals, so isolated readings can be difficult to interpret. Insulin-like growth factor 1 changes more slowly and is often treated as the more stable integrated marker of axis activity.
Because growth hormone is released in pulses, single measurements can misrepresent overall secretion. Investigators sometimes use repeated sampling or overnight profiles to capture the pattern rather than a single value. Provocative testing, in which a stimulus is given and the response is tracked over time, offers another way to characterize the axis. Each approach carries trade-offs between sensitivity, burden on the participant, and the influence of non-target variables.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide | GHRH analog family |
| Residue count | 44 amino acids | Matches human GHRH(1-44) backbone |
| N-terminal group | trans-3-hexenoyl | Main structural difference from native hormone |
| Appearance | White to off-white powder | Lyophilized solid form |
| Solubility class | Freely soluble in water | Peptide character; less soluble in organic solvents |
A documented effect of tesamorelin is a reduction in visceral adipose tissue in some study populations. Researchers have reported decreases in trunk fat measured by computed tomography alongside changes in lipid markers. The mechanism is thought to involve growth hormone-mediated lipolysis, though the precise contribution of direct versus indirect pathways is not fully resolved. Studies have generally examined defined groups over finite periods, so long-term outcomes are less well characterized. Findings have not been uniform across all trials.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone (GHRH). Its sequence corresponds to the 44-amino-acid form of human GHRH with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification slows enzymatic cleavage and extends the peptide's activity relative to the native hormone. The compound is produced by solid-phase peptide synthesis and supplied as a lyophilized powder. Researchers classify it as a GHRH receptor agonist. Its structure places it in the same family as other growth hormone secretagogues that act on the pituitary.
Stimulated growth hormone release leads to hepatic production of insulin-like growth factor 1, a key mediator of many growth hormone effects. In clinical studies, tesamorelin increased IGF-1 levels in a dose-dependent manner, although the response varies among individuals. The drug's effect on visceral fat is thought to involve growth hormone-mediated lipolysis and altered adipocyte metabolism. Muscle mass and lean body mass have also been assessed as secondary outcomes, but changes are generally smaller and less consistent than fat reductions.
Pharmacodynamic studies show that tesamorelin reduces visceral adipose tissue more than subcutaneous adipose tissue in the studied population. This selectivity may relate to differences in blood flow and hormone sensitivity between fat depots. Effects on glucose metabolism and insulin sensitivity have been investigated, with some trials reporting modest changes and others showing stability. The precise relationship between growth hormone exposure, IGF-1 levels, and visceral fat loss remains an active area of analysis.
=== Alkylation of carboxylic acids and their salts === Trimethyloxonium tetrafluoroborate can be used for esterification of carboxylic acids under conditions where acid-catalyzed reactions are infeasible:
Cardiac muscle forms both the atria and the ventricles of the heart. Although this muscle tissue is very similar between cardiac chambers, some differences exist. The myocardium found in the ventricles is thick to allow forceful contractions, while the myocardium in the atria is much thinner. The individual myocytes that make up the myocardium also differ between cardiac chambers. Ventricular cardiomyocytes are longer and wider, with a denser T-tubule network. Although the fundamental mechanisms of calcium handling are similar between ventricular and atrial cardiomyocytes, the calcium transient is smaller and decays more rapidly in atrial myocytes, with a corresponding increase in calcium buffering capacity. The complement of ion channels differs between chambers, leading to longer action potential durations and effective refractory periods in the ventricles. Certain ion currents such as IK(UR) are highly specific to atrial cardiomyocytes, making them a potential target for treatments for atrial fibrillation.
=== Division of Israel and Judah === The monarchic state was divided into two states, Israel and Judah, due to civil and religious disputes. Eventually, Israel and Judah met their demise after the Assyrian and Babylonian invasions respectively. According to the Biblical prophets, these invasions were divine judgements for religious apostasy and corrupt leadership. This period is covered by 1 Kings 12 to 2 Kings 25 or alternatively, 2 Chronicles 10 to 2 Chronicles 36. The Book of Jonah narrates the prophet Jonah going to the Neo-Assyrian Empire to deliver a divine message.
==== Deka Machines ==== The Deka Machines (デカマシン, Deka Mashin) are vehicle-themed mecha that are dispatched from the Deka Base and can combine into giant robots through either Tokusou Combination (特捜合体, Tokusō Gattai) or Tokusou Transformation (特捜変形, Tokusō Henkei).
Sources: en.wikipedia.org
== Social effects == A non-smoker who is inhaling sidestream or second-hand smoke has a 30% greater risk of getting lung cancer at some point in their lives. Exposure to second hand or sidestream smoke has been associated with people who have not smoked before. The US Environmental Protection Agency estimates sidestream smoke causes approximately 3,000 lung cancer deaths and 62,000 deaths from heart disease in non-smokers every year in the United States.
=== 70S scanning model === When translating a polycistronic mRNA, a 70S ribosome ends translation at a stop codon. It is now shown that instead of immediately splitting into its two halves, the ribosome can "scan" forward until it hits another Shine–Dalgarno sequence and the downstream initiation codon, initiating another translation with the help of IF2 and IF3. This mode is thought to be important for the translation of genes that are clustered in poly-cistronic operons, where the canonical binding mode can be disruptive due to small distances between neighboring genes on the same mRNA molecule.
== History == Approval by the US Food and Drug Administration (FDA) was based on TRIDENT-1, a global, multicenter, single-arm, open-label, multi-cohort clinical trial (NCT03093116) which included participants with ROS1-positive locally advanced or metastatic non-small cell lung cancer. Efficacy was evaluated in 71 ROS1 tyrosine kinase inhibitor-naïve participants who received up to one prior line of platinum-based chemotherapy and/or immunotherapy and 56 participants who received one prior ROS1 tyrosine kinase inhibitor with no prior platinum-based chemotherapy or immunotherapy. The FDA granted the application for repotrectinib priority review, breakthrough therapy, and fast track designations.
=== Other uses === Test tubes are sometimes put to casual uses outside of lab environments, e.g. as flower vases, glassware for certain weak shots, or containers for spices. They can also be used for raising queen ants during their first months of development.
And when I got it, I didn't miss it." The Astros and Bagwell agreed to a four-year contract on November 23, 1994, worth $27.5 million (USD, $59.7 million today) with the three option years. The average annual value of $6.875 million ($14.9 million today) made him the fifth-highest paid player in the majors.
Sources: en.wikipedia.org
== Awards == 1988 Du Vigneaud Award for Young Investigators in Peptide Research 1989 Protein Society Young Investigator Award 1992 Eli Lilly Award in Biological Chemistry 1993 DuPont Merck Summit Award 1995 Fellow, American Association for the Advancement of Science 1998 Fellow, AAAS 1999 Member, National Academy of Sciences (U.S.A.) 2003 The American Peptide Society Merrifield Award 2008 The American Chemical Society Ralph F. Hirschmann Award in Peptide Chemistry 2009 The American Peptide Society Makineni Award 2015 The Stein & Moore Award of the Protein Society 2016 Weizmann Institute Max Perutz Memorial Lecture 2018 The American Chemical Society Cope Scholar Award 2018 The American Chemical Society Murray Goodman Memorial Prize 2020 The Franklin Institute & City Council of Philadelphia John C. Scott Award 2025 ACS Ronald Breslow Award for Achievement in Biomimetic Chemistry
== Natural and synthetic cannabinoids == The following are banned for in-competition use only, with the exception of cannabidiol (CBD) which is not banned for any use. In 2013, the level of THC metabolite allowed was changed from 15 ng/mL to 150 ng/mL so as to only detect in-competition use.
=== Symmetrical flow === Of these techniques flow FFF was the first to be offered commercially. Flow FFF separates particles based on size, independent of density and can measure macromolecules in the range of 1 nm to 1 μm. In this respect it is the most versatile FFF sub-technique available. The cross flow in Flow FFF enters through a porous frit at the top of the channel, exiting through a semi-permeable membrane outlet frit on the accumulation wall (i.e. the bottom wall). Symmetrical flow has been replaced by asymmetrical flow in the last two decades.
== Biography == Born in Mwan in 1902, Mailo was educated at the Protestant Mission School at Anopouou. After leaving school in 1914, he worked on a trading boat between 1915 and 1920. The Japanese authorities appointed Mailo to the post of secretary of Moen island in 1932. The following year, he succeeded his uncle as Chief of Nepukos village. In 1936 he became Leader of Section No. 2 of Moen island, holding the role until 1938. Between 1939 and 1944 he was employed by the Japanese government as an advisor on native affairs. In 1947 he became Chief of Moen, succeeding his brother Albert. In 1957 the position was reconstituted as a mayoral post and made elective, with Mailo elected to the post. In the same year, he was elected to Truk Congress, serving as president of the legislature in 1957 and 1958. He also became president of the Truk Trading Company. In 1965 Mailo was elected to the General Assembly of the new Congress of the Trust Territory of the Pacific Islands as the Moen representative. The body was later renamed the House of Representatives and Mailo was re-elected in 1966, remaining in office until the 1968 elections. He subsequently served on the board of Air Micronesia. He died in Truk Hospital in September 1971 at the age of 68, survived by wife Chimako and eleven children.
Sources: en.wikipedia.org
No. It is a peptide that acts upstream of growth hormone release, while growth hormone is the hormone itself. The two differ in size, in receptor, and in how the body clears them.
It blocks the amino-terminal degradation step that limits native GHRH. The addition extends how long the peptide survives in plasma without removing its ability to activate the receptor.
The chain contains 44 amino acid residues. It matches the human GHRH(1-44) sequence apart from the amino-terminal modification.
It varies slowly and reflects cumulative axis activity rather than momentary secretion. Growth hormone is released in pulses affected by sleep, stress, and meals, making single readings hard to interpret. The slower marker gives a more stable picture across a study period.